Difficult Atrial Fibrillation Rate-Control and Digitalis Toxicity in Mitral-Valve Prolapse Patient with Hyperthyroidism | Cardiovascular and Cardiometabolic Journal (CCJ)

Difficult Atrial Fibrilation Rate-Control and Digitalis Toxicity in Mitral-Valve Prolapse Patient with Hyperthyroidism

Authors

Suryo Ardi Hutomo
suryo.ardi.hutomo-2015@fk.unair.ac.id
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga
Agus Subagjo Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga

Vol. 1 No. 2 (2020): Cardiovascular and Cardiometabolic Journal

Case Report

September 19, 2020

Versions

2020-09-19 (2)
2020-09-19 (1)

Rate-control is important management in patient with atrial fibrillation. The optimum rate control provides a decrease of symptoms, improves hemodynamics and prevents tachycardia-induced cardiomyopathy. Rate-control could be difficult to achieve because of patient's comorbidities and special treatment strategy is needed to resolve it. A-46-yo. male, came to ER with palpitation. Holosystolic murmur was heard at apex, radiating to axilla. ECG showed atrial fibrillation, with rapid ventricular response 180 bpm. Echocardiography showed dilated LA and LV, false-normal LV function with EF 59% and anterior mitral-valve prolapse with moderate mitral regurgitation. Acute treatment was administration of digoxin and beta blockers, but ventricular rate wasn't controlled, until 1.5 mg doses of digoxin was administered. Then patient develops acute digitalis intoxication. After toxicity management, rapid ventricular rate recurs. Patient reevaluation showed hyperthyroidism with low TSH and high T4. Methimazole and propranolol was given and rate-control was achieved shortly after euthyroid state, in 2 months treatment. This patient suffered difficult rate-control despite guidelines-based management. Digitalis intoxication was developed after administration of several therapeutic doses. The diagnosis of hyperthyroidism is central in management of this case. Coexistent of hyperthyroidism and mitral-valve prolapse may be explained by genetic, autoimmune, and thyroid hormone effects in myocardium.

Hutomo, S. A., & Subagjo, A. (2020). Difficult Atrial Fibrilation Rate-Control and Digitalis Toxicity in Mitral-Valve Prolapse Patient with Hyperthyroidism. Cardiovascular and Cardiometabolic Journal (CCJ), 1(2), 57–68. https://doi.org/10.20473/ccj.v1i2.2020.57-68

Download Citation

Yuniadi Y, Tondas AE, Hanafy DA, Hermanto DY, Maharani E, Munawar M, et al. Pedoman Tata Laksana Fibrilasi Atrium Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. 2014;54–5.

Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):1609–78.

Kuznar W. New Drug Therapies for Difficult-to-Control Atrial Fibrillation [Internet]. Value-Based Care in Cardiometabolic Health , Vol 1, No 1. 2012 [cited 2017 Jun 17]. Available from: http://www.ahdbonline.com/issues/value-based-care-cardiometabolic-health/may-2012-vol-1-no-1/1015-article-1015

January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of cardiology/American heart association task force on practice guidelines and the heart rhythm society. Vol. 130, Circulation. 2014. 199–267 p.

The Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Investigators. A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation. N Engl J Med. 2002;347(23):1825–33.

Heist EK, Mansour M, Ruskin JN. Rate control in atrial fibrillation: Targets, methods, resynchronization considerations. Circulation. 2011;124(24):2746–55.

Van Gelder IC, Rienstra M, Crijns HJGM, Olshansky B. Rate control in atrial fibrillation. Lancet [Internet]. 2016;388(10046):818–28. Available from: http://dx.doi.org/10.1016/S0140-6736(16)31258-2

Medscape. Lanoxin (digoxin) dosing, indications, interactions, adverse effects, and more [Internet]. Medscape.com. 2015 [cited 2017 Jul 27]. Available from: http://reference.medscape.com/drug/lanoxin-digoxin-342432

Grais IM, Sowers JR. Thyroid and the Heart. Am J Med [Internet]. 2014 Aug;127(8):691–8. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0002934314002368

Klein I. Endocrine disorders and cardiovascular disease. In: Mann DL, Zipes DL, Libby P, Bonow RO, editors. A Textbook of Cardiovascular Medicine. 10th ed. Elsevier-Saunders; 2015. p. 1798–805.

Shimizu T, Koide S, Noh JY, Sugino K, Ito K, Nakazawa H. Hyperthyroidism and the management of atrial fibrillation. Thyroid [Internet]. 2002;12(6):489–93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12165111

Fadel BM, Ellahham S, Ringel MD, Lindsay J, Wartofsky L, Burman KD. Hyperthyroid heart disease. Clin Cardiol. 2000;23:402–8.

Jayaprasad N, Johnson F. Atrial fibrillation and hyperthyroidism. Indian Pacing Electrophysiol J. 2005;5(4):305–11.

Bielecka-Dabrowa A, Mikhailidis DP, Rysz J, Banach M. The mechanisms of atrial fibrillation in hyperthyroidism. Thyroid Res [Internet]. 2009;2(1):4. Available from: http://thyroidresearchjournal.biomedcentral.com/articles/10.1186/1756-6614-2-4

Issa ZF, Miller JM, Zipes DP. Atrial Fibrillation. In: Clinical Arrhythmology and Electrophysiology : a Companion to Braundwald's Heart Disease. 1st ed. Saunders - Elsevier; 2009. p. 208–86.

Kim D, Smith TW. Effects of thyroid hormone on sodium pump sites, sodium content, and contractile responses to cardiac glycosides in cultured chick ventricular cells. J Clin Invest. 1984;74(4):1481–8.

Busti AJ. Why Propranolol is preferred to other beta-blockers in thyrotoxicosis or thyroid storm? Evidence-Based Medicine Consult. 2015.

Murakami S, Nasu M, Fukayama H, Krishnan L, Sugawara M. Propranolol has direct antithyroid activity: Inhibition of iodide transport in cultured thyroid follicles. Cell Biochem Funct. 1993;11(3):159–65.

Bayer MJ. Recognition and management of digitalis intoxication: Implications for emergency medicine. Am J Emerg Med. 1991;9(2 SUPPL. 1):29–32.

Panampalam. Digoxin toxicity : Case report. BMJ Best Pract [Internet]. 2014;(2):9954. Available from: http://bestpractice.bmj.com/best-practice/monograph/338.html

Pincus M. Management of digoxin toxicity. Aust Prescr. 2016;39(1):18–20.

Ma G, William J B, Pollack M, Chan TC. Electrocardiographic manifestations: digitalis toxicity. J Emerg Med. 2001;20(2):145–52.

Lip GY, Metcalfe MJ, Dunn FG. Diagnosis and treatment of digoxin toxicity. Postgrad Med J [Internet]. 1993;69(811):337–9. Available from: http://pmj.bmj.com/cgi/doi/10.1136/pgmj.69.811.337

Gómez AL. Digitalis intoxication. Am Heart J. 1972;84(2):285.

Williams RH, Erickson T. Evaluating Digoxin and Theophylline Intoxication in the Emergency Setting. Lab Med. 1998;29(March):158–61.

Bismuth C, Gaultier M, Conso F, Efthymiou ML. Hyperkalemia in acute digitalis poisoning: prognostic significance and therapeutic implications. Clin Toxicol [Internet]. 1973;6(2):153–62. Available from: http://www.ncbi.nlm.nih.gov/pubmed/4715199

Williamson KM, Thrasher KA, Fulton KB, Lapointe NMA, Dunham GD, Cooper AA, et al. Digoxin toxicity: an evaluation in current clinical practice. Arch Intern Med. 1998;158:2444–9.

Channick BJ, Adlin EV, Marks AD, Denenberg BS, McDonough MT, Chakko CS, et al. Hyperthyroidism and mitral-valve prolapse. N Engl J Med. 1988;319(26).

Brauman A, Algom M, Gilboa Y, Ramot Y, Golik A, Stryjer D. Mitral valve prolapse in hyperthyroidism of two different origins. Br Heart J [Internet]. 1985;53(4):374–7. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=481774&tool=pmcentrez&rendertype=abstract

Baştuğ S, Sarı C, Aslan AN, Bayram NA, Ayhan H, Kasapkara HA, et al. Evaluation of autoimmune thyroid disease in patients with mitral valve prolapse. Erciyes Med J. 2015;37(3):98–101.